INFIQ (Infinity Pharmaceuticals) Research & Development: $27.08 Mil (TTM As of Jun. 2023)


INFIQ Infinity Pharmaceuticals Inc INFIQ
16 GF Score
Price $0.00
View Full Analysis

What is Infinity Pharmaceuticals Research & Development?

Infinity Pharmaceuticals INFIQ -99.00% 16 Research & Development is $27.08 Mil as of Jun. 2023. GuruFocus rates INFIQ with a GF Score™ of 16/100.

Research & Development is the aggregate amount of research and development expenses during the year. Infinity Pharmaceuticals's Research & Development for the three months ended in Jun. 2023 was $6.60 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $27.08 Mil.

Infinity Pharmaceuticals  (OTCPK:INFIQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Infinity Pharmaceuticals Research & Development Related Terms

Infinity Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Infinity Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infinity Pharmaceuticals Research & Development Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.76 27.12 26.76 31.65 32.41

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.80 7.66 6.96 5.85 6.60
INFIQ
16GF Score
Infinity Pharmaceuticals Inc INFIQ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infinity Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $27.08 Mil mean?
Infinity Pharmaceuticals (INFIQ) has a Research & Development of $27.08 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on Infinity Pharmaceuticals and its competitors.
Is Infinity Pharmaceuticals' Research & Development too high?
Infinity Pharmaceuticals' current Research & Development is $27.08 Mil. Overall, Infinity Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Infinity Pharmaceuticals' Research & Development compare to CLCS and RVLPQ?
Infinity Pharmaceuticals' Research & Development of $27.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Infinity Pharmaceuticals and its competitors. Infinity Pharmaceuticals's current Research & Development is $27.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinity Pharmaceuticals stock overvalued right now?
Infinity Pharmaceuticals (INFIQ) has a current Research & Development of $27.08 Mil. The current Research & Development is $27.08 Mil. Infinity Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Infinity Pharmaceuticals (INFIQ), the current Research & Development is $27.08 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infinity Pharmaceuticals Business Description

Address 1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
16GF Score

Get the complete analysis for INFIQ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price